AG˹ٷ

STOCK TITAN

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Haleon (NYSE: HLN) has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025. Haney joins from Estée Lauder Companies Inc., where he served as Executive Vice President of Global Innovation and R&D for 13 years, following a 20-year tenure at P&G.

Haney succeeds Franck Riot, who is departing after six years with the company. CEO Brian McNamara highlighted Haney's expertise in driving transformative innovation within global consumer businesses, emphasizing his role in implementing Haleon's new Win as One strategy.

Haleon (NYSE: HLN) ha nominato Carl Haney come Chief Research & Development Officer, con decorrenza dal 1 agosto 2025. Haney arriva da Estée Lauder Companies Inc., dove ha ricoperto per 13 anni il ruolo di Executive Vice President of Global Innovation and R&D, dopo un'esperienza ventennale in P&G.

Haney sostituisce Franck Riot, che lascia l'azienda dopo sei anni. Il CEO Brian McNamara ha sottolineato l'esperienza di Haney nel guidare innovazioni trasformative in aziende globali del settore consumer, evidenziando il suo contributo nell'attuazione della nuova strategia Win as One di Haleon.

Haleon (NYSE: HLN) ha nombrado a Carl Haney como Director de Investigación y Desarrollo, con efecto a partir del 1 de agosto de 2025. Haney proviene de Estée Lauder Companies Inc., donde fue Vicepresidente Ejecutivo de Innovación Global e I+D durante 13 años, tras una trayectoria de 20 años en P&G.

Haney reemplaza a Franck Riot, quien se retira después de seis años en la empresa. El CEO Brian McNamara destacó la experiencia de Haney en impulsar innovaciones transformadoras en negocios globales de consumo, enfatizando su papel en la implementación de la nueva estrategia Win as One de Haleon.

Haleon (NYSE: HLN)Carl Haney� 2025� 8� 1�부� 최고 연구개발 책임�(Chief Research & Development Officer)� 임명했습니다. Haney� Estée Lauder Companies Inc.에서 13년간 글로벌 혁신 � 연구개발 부� 부사장(Executive Vice President)� 역임했으�, � 이전에는 P&G에서 20년간 근무했습니다.

Haney� 6년간 근무� Franck Riot� 후임입니�. CEO Brian McNamara� Haney가 글로벌 소비� 기업에서 혁신� 주도� 전문성을 강조하며, Haleon� 새로� Win as One 전략 실행� 있어 그의 역할� 부각시켰습니다.

Haleon (NYSE : HLN) a nommé Carl Haney au poste de Chief Research & Development Officer, à compter du 1er août 2025. Haney rejoint l'entreprise après avoir passé 13 ans chez Estée Lauder Companies Inc. en tant que Vice-Président Exécutif de l'Innovation et de la R&D mondiale, précédé d'une carrière de 20 ans chez P&G.

Haney succède à Franck Riot, qui quitte l'entreprise après six ans. Le PDG Brian McNamara a souligné l'expertise de Haney dans la conduite d'innovations transformatrices au sein d'entreprises mondiales de consommation, mettant en avant son rôle dans la mise en œuvre de la nouvelle stratégie Win as One de Haleon.

Haleon (NYSE: HLN) hat Carl Haney zum Chief Research & Development Officer ernannt, wirksam ab dem 1. August 2025. Haney kommt von Estée Lauder Companies Inc., wo er 13 Jahre lang als Executive Vice President für globale Innovation und F&E tätig war, nach einer 20-jährigen Laufbahn bei P&G.

Haney folgt auf Franck Riot, der nach sechs Jahren das Unternehmen verlässt. CEO Brian McNamara hob Haneys Expertise bei der Förderung transformativer Innovationen in globalen Konsumgüterunternehmen hervor und betonte seine Rolle bei der Umsetzung der neuen Win as One-Strategie von Haleon.

Positive
  • Appointment of experienced R&D executive with over 33 years of experience in global consumer businesses
  • Strategic alignment with company's Win as One strategy and transformation goals
  • Strengthening of executive leadership team with expertise in transformative innovation
Negative
  • Departure of current R&D Officer Franck Riot after 6 years indicates potential disruption in R&D leadership continuity

LONDON, June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE: HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. 

This appointment follows Franck Riot deciding to leave Haleon after six years in the business. 

Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. 

Brian McNamara, Haleon's Chief Executive Officer commented:

"I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon's significant potential through our new Win as One strategy. 

"I want to take this opportunity to thank Franck for his significant contribution to Haleon over the last six years. He has played an important role in the lead up to and beyond separation to move our innovation agenda forward and prepare us for the next phase of our journey. On behalf of everyone at Haleon, I wish him the very best for the future."

Carl Haney commented:

"I am hugely excited to be joining Haleon at such an important stage of its journey, as it looks to capitalise on the significant opportunities ahead and continues its transformation into a world class consumer company. I am incredibly passionate about the role that R&D can play in delivering Haleon's ambitions and its purpose of delivering better everyday health with humanity. I am very much looking forward to meeting the team and getting started in August."

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, TherafluԻVoltaren - are built on trusted science, innovation and deep human understanding.

Photo - https://mma.prnewswire.com/media/2717039/Haleon.jpg

Cision View original content to download multimedia:

SOURCE Haleon

FAQ

Who is the new Chief R&D Officer at Haleon (NYSE: HLN)?

Carl Haney has been appointed as Haleon's new Chief R&D Officer, effective August 1, 2025.

What is Carl Haney's previous experience before joining Haleon?

Carl Haney was Executive Vice President of Global Innovation and R&D at Estée Lauder Companies for 13 years and spent over 20 years at P&G across Home, Health and Beauty Care.

Who did Carl Haney replace as Haleon's R&D Officer?

Carl Haney replaces Franck Riot, who is leaving Haleon after six years with the business.

When will Carl Haney start his role at Haleon (HLN)?

Carl Haney will join Haleon on August 1, 2025.

What is Haleon's new strategy mentioned in the announcement?

The announcement references Haleon's new Win as One strategy, which aims to unlock the company's significant potential.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

46.81B
4.49B
0.02%
11.99%
0.59%
Drug Manufacturers - Specialty & Generic
Healthcare
United Kingdom
Weybridge